Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with Relapsed/Refractory Acute Myeloid Leukemia

Phase I, first-in-human, open-label, dose-escalation and dose-expansion study evaluating the
safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute
myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical
activity of UCART123v1.2 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase
2 Dose (RP2D).

Main Inclusion Criteria:

- Patients with relapsed or primary refractory AML (as defined in WHO criteria) with >5%
bone marrow blasts

- Patients with CD123+ blast cells (verified by flow cytometry)

- Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of ≤1

- Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac
function based on the last assessment performed within screening period

- (Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion
(LD)

- Other criteria may apply

Main Exclusion Criteria:

- Patients with APL or CNS Leukemia

- Previous investigation gene or cell therapy (including CAR)

- ≥ 2 prior allogeneic SCTs

- Prior treatment with rituximab or other anti-CD20 therapy within 3 months

- Any known active or uncontrolled infection

- Other criteria may apply